The rapamycin treatment was found to inhibit the progression of AD and increase the life span in the diseased model of AD.193 Rapamycin is used in clinical settings and has shown promising effectiveness against AD and emerged as a potential therapeutics.194 Dactolisib treatment was shown to protect the AD in a transgenic murine Alzheimer model.195 In the future, next-generation mTOR inhibitors can be designed and tested in AD and PD mice models for better drugs. Here, MTOR is linked to Parkinson disease.